Protocol Ledger

NCT03703791 · Phase III · TERMINATED

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Interventional Phase III clinical trial protocol NCT03703791 sponsored by Aimmune Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-24 Enrollment: 1 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03703791
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03703791
Protocol FieldVerified Registry Value
NCT IdentifierNCT03703791
Consolidated Lead SponsorAimmune Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment1 participants (ACTUAL)
Registered Start Date2018-10-24
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03703791
Hospital Research SiteLocationSite Profile
Hospital Universitario Infanta LeonorMadrid, SpainOpen Hospital Dossier ->
Hospital Clinico San CarlosMadrid, SpainOpen Hospital Dossier ->
Complejo Hospitalario de NavarraPamplona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI